Background
==========

Hypothyroidism is a recognized side effect of thalidomide drugs. We herein report a case of 83-year-old Irish female with a diagnosis of multiple myeloma and a background history of type 2 diabetes mellitus and hypertension.

Case presentation
=================

An 83-year-old female with a background history of type 2 diabetes mellitus for 25 years complicated by diabetic retinopathy and hypertension was diagnosed with IgG kappa multiple myeloma in September 2011. She presented with gradual onset of malaise, anorexia and fatigue. Her investigation showed normocytic anemia (hemoglobin level of 10.1 (g/dL) (reference range: 12.3--15.3 g/dL) with an elevated ESR of 112 mm/h (reference range: 1--20 mm/h). Colonoscopy investigation was normal, and she was referred to the hematology department for further investigations. Serum protein electrophoresis (SPEP) revealed a high-normal serum total protein of 80 g/L (reference range: 60--80 g/L), with elevated serum globulin (45 g/L, reference range: 18--36 g/L) and IgG level (24.20 g/L, reference range: 7.00--16.00 g/L). Additionally investigation showed, serum light chain elevated kappa light chain (98.0 mg/L, reference range: 3.3--19.4 mg/L), normal lambda light chain (7.8 mg/L, reference range: 5.71--26.3 mg/L), with an elevated kappa-to-lambda ratio (12.564, reference range: 0.310--1.200). Beta 2 microglobulin was normal, and her urine was negative for Bence Jones protein (BJP). A skeletal survey revealed no lytic lesions and a bone marrow aspirate and trephine biopsy revealed 10--15% plasma cells, stained positive for CD138. She had elevated serum urea (12.9 mmol/L (reference range: 2.8--8.6 mmol/L)) and Creatinine level (112 μmol/L (reference range: 46--86 μmol/L)) with and normal calcium and albumin levels.

Our patient was commenced on 6 cycles of cyclophosphamide, thalidomide and dexamethasone (CTD) between September 2011 and March 2012 and achieved a very good partial response, but unfortunately relapsed in 2013. She was treated with bortezomib and dexamethasone followed by cyclophosphamide, bortezomib and dexamethasone (CyBorD) for 6 cycles and achieved a good response. Unfortunately, she had a second relapse in February 2016, whereby she was treated with one cycle of lenalidomide and prednisolone. Lenalidomide was discontinued in March 2016 due to acute kidney injury. She was recommenced on bortezomib and prednisolone for another 5 cycles but her response was poor. In February 2017, she was commenced on pomalidomide 3 mg. She had normal thyroid function test prior to pomalidomide treatment. After 4 weeks of initiation of pomalidomide, she presented with worsening fatigue. Our patient had not had any family history of thyroid disorder. Her clinical examinations were normal including no palpable goiter or lymphadenopathy. Her thyroid function test revealed profound hypothyroidism with low fT4 at 7.2 (pmol/L) (reference range: 9.0--20.0 pmol/L) and an elevated TSH at 44.7mIU/L (reference range: 0.35--4.94 mIU/L). She was reviewed by the endocrinology specialty and was commenced on levothyroxine 50 µg daily and dose was increased to 100 µg daily over four weeks. Her thyroid peroxidase antibody (TPO Ab) was -- positive 405.8 IU/mL (reference range \<5.6). Thyroid ultrasound showed heterogeneous thyroid gland, which suggestive of thyroiditis with no evidence of lymphadenopathy or suspicious nodules. Our patient was reviewed recently in endocrinology outpatient department with a good clinical and biochemical response and recent thyroid function test was normal, a FT4 of 14.2 pmol/L and TSH 1.10 mIU/L.

Investigation
=============

Thyroid function test revealed profound hypothyroidism with low fT4 at 7.2 pmol/L (reference range: 9.0--20.0 pmol/L) and an elevated TSH at 44.7 mIU/L.

Thyroid peroxidase antibody (TPO Ab) was positive -- 405.8 IU/mL (reference range ˂5.6).

Thyroid ultrasound showed heterogeneous thyroid gland, which is suggestive of thyroiditis with no evidence of lymphadenopathy or suspicious nodules.

Treatment
=========

Commenced on levothyroxine 50 µg daily, and dose was increased to 100 µg daily over four weeks.

Outcome and follow-up
=====================

Patient was reviewed recently in endocrinology outpatient department with a good clinical and biochemical response and recent thyroid function test was normal, a FT4 of 14.2 pmol/L and TSH 1.10 mIU/L.

Discussion
==========

Pomalidomide is a third-generation immunomodulatory agent, a derivative of thalidomide, that is currently reserved for the treatment of patients with relapsed/refractory multiple myeloma. It works by inducing cell cycle arrest and apoptosis directly in multiple myeloma cells; enhances T-cell- and natural killer (NK) cell-mediated cytotoxicity; inhibits production of proinflammatory cytokines tumor necrosis factor-α (TNF-α), IL-1, IL-6 and IL-12 and inhibits angiogenesis ([@bib1]). Neutropenia is the most common side effect of pomalidomide reported in up to 26--66% of patients treated while other common side effects includes anemia and thrombocytopenia ([@bib2]). Fatigue, thromboembolic events, skin toxicities, hyperglycemia and peripheral neuropathies were considered to be the non-hematological adverse reactions of pomalidomide ([@bib3]).

Thyroidal dysfunctions is a well-known side effect of certain antineoplastic agents through different mechanisms ([Table 1](#tbl1){ref-type="table"}) ([@bib4]). Pomalidomide toxicities were studied previously but none mentioned any relation between hypothyroidism and pomalidomide ([@bib2]). Hamadeh and coworkers described the first case of pomalidomide-induced hypothyroidism (2015) in a 51-year-old female, diagnosed with multiple myeloma, and she developed overt hypothyroidism after the fourth cycle of pomalidomide ([@bib5]). Unlike pomalidomide, thalidomide and lenalidomide may lead to hypothyroidism. Up to 20% of patients receiving thalidomide for multiple myeloma developed serum TSH greater than 5 IU/L, while 7% had a TSH greater than 10 IU/L ([@bib6]). Additionally, up to 6% of patients with no previous history of thyroid dysfunction who received lenalidomide developed hypothyroidism in a retrospective study ([@bib7]). Table 1Antineoplastic and thyroidal dysfunctions.AgentLikely mechanism of effect on thyroidClinical manifestationsAverage time from first exposure to onsetFrequency of thyroid dysfunctionPrimary hypothyroidism Tyrosine kinase inhibitors  Imatinib, sorefanib, motesanibPreexisting LT4 therapy: increase clearance of LT4Increased LT4 requirement\<2 weeks21%--100%  Sunitinib, dasatinib, nilotinib, axitinib, cediranibPreviously euthyroid patients: angiogenic activityHypothyroidism, occasionally preceded by mild thyrotoxicosis.4--94 weeks18%--85% Immuno-therapies  Interferon-α, Alemtuzumab, IpilimumabStimulation of autoimmunityHashimoto thyroiditis1--6 month5%--50% Immunomodulatory\
Thalidomide, LenalidomideT-cell stimulation, antiangiogenic activity, and induction of cytokine releaseIschemic or autoimmune thyroiditis1--6 month\
Median: 5 months7%\
5%--10%Secondary or central hypothyroidism BexaroteneDecreased TSHB gene expression, reduced secretion of TSHCentral hypothyroidismHours-days\>90% Immuno-therapies  Ipilimumab, tremelimumabImmune dysregulation with hypophysitisCentral hypothyroidism9--24 week5%--17%Hyperthyroidism Immuno-therapies  Ipilimumab, tremelimumabImmune dysregulationGraves' disease or painful thyroiditis1--3 monthRare  AlemtuzumabImmune reconstitution abnormalitiesGraves' disease or painful thyroiditis6--31 month10%--30%  Interferon-αImmune reconstitution abnormalitiesGraves' disease or painful thyroiditis4--9 month1%

Pomalidomide have similar features of thalidomide ([@bib8]). Several mechanisms have been suggested in the pathogenesis of thalidomide-induced hypothyroidism. These include inhibition of thyroid hormone secretion ([@bib9]), reduction of iodine uptake into follicular thyroid cells ([@bib10]) an anti-angiogenic effect disrupting the blood flow to the thyroid ([@bib6]) and through an autoimmune thyroiditis process induced by deregulation of cytokine or direct effects of T-lymphocytes ([@bib6]).

It is plausible that these mechanisms may be true for pomalidomide-induced hypothyroidism; however, further studies are needed to prove this relationship. Based on this case and others ([@bib5]), we recommend measuring TSH before and then every 2--3 months while on pomalidomide as recommended ([@bib9]).

In conclusion, overt hypothyroidism is a potential adverse effect of pomalidomide therapy. Practitioners prescribing this drug should be aware of this potential side effect and thyroid function test should be included as a screening test with regular review in patients receiving pomalidomide. Resumption of treatment with pomalidomide is not contraindicated once the hypothyroidism has been adequately treated.
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